Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/GMPS_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/GMPS_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GMPS_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GMPS_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GMPS_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GMPS_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GMPS_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000616418 | Skin | cSCC | purine nucleotide biosynthetic process | 73/4864 | 191/18723 | 1.28e-04 | 1.17e-03 | 73 |
GO:00091679 | Skin | cSCC | purine ribonucleoside monophosphate metabolic process | 22/4864 | 41/18723 | 1.46e-04 | 1.31e-03 | 22 |
GO:00091616 | Skin | cSCC | ribonucleoside monophosphate metabolic process | 28/4864 | 58/18723 | 2.14e-04 | 1.77e-03 | 28 |
GO:00091244 | Skin | cSCC | nucleoside monophosphate biosynthetic process | 22/4864 | 42/18723 | 2.31e-04 | 1.90e-03 | 22 |
GO:00460378 | Skin | cSCC | GMP metabolic process | 10/4864 | 16/18723 | 2.25e-03 | 1.32e-02 | 10 |
GO:00091274 | Skin | cSCC | purine nucleoside monophosphate biosynthetic process | 12/4864 | 21/18723 | 2.40e-03 | 1.38e-02 | 12 |
GO:00091134 | Skin | cSCC | purine nucleobase biosynthetic process | 7/4864 | 10/18723 | 4.43e-03 | 2.29e-02 | 7 |
GO:00091564 | Skin | cSCC | ribonucleoside monophosphate biosynthetic process | 16/4864 | 33/18723 | 4.50e-03 | 2.30e-02 | 16 |
GO:00091125 | Skin | cSCC | nucleobase metabolic process | 16/4864 | 34/18723 | 6.47e-03 | 3.15e-02 | 16 |
GO:00461124 | Skin | cSCC | nucleobase biosynthetic process | 10/4864 | 18/18723 | 7.25e-03 | 3.44e-02 | 10 |
GO:001969327 | Thyroid | PTC | ribose phosphate metabolic process | 176/5968 | 396/18723 | 8.28e-08 | 1.70e-06 | 176 |
GO:000915028 | Thyroid | PTC | purine ribonucleotide metabolic process | 165/5968 | 368/18723 | 1.03e-07 | 2.05e-06 | 165 |
GO:007252127 | Thyroid | PTC | purine-containing compound metabolic process | 182/5968 | 416/18723 | 1.92e-07 | 3.51e-06 | 182 |
GO:000925927 | Thyroid | PTC | ribonucleotide metabolic process | 170/5968 | 385/18723 | 2.32e-07 | 4.08e-06 | 170 |
GO:000616327 | Thyroid | PTC | purine nucleotide metabolic process | 170/5968 | 396/18723 | 2.02e-06 | 2.75e-05 | 170 |
GO:000675325 | Thyroid | PTC | nucleoside phosphate metabolic process | 205/5968 | 497/18723 | 5.24e-06 | 6.35e-05 | 205 |
GO:000911725 | Thyroid | PTC | nucleotide metabolic process | 202/5968 | 489/18723 | 5.46e-06 | 6.60e-05 | 202 |
GO:000915224 | Thyroid | PTC | purine ribonucleotide biosynthetic process | 78/5968 | 169/18723 | 6.88e-05 | 6.01e-04 | 78 |
GO:004639024 | Thyroid | PTC | ribose phosphate biosynthetic process | 85/5968 | 190/18723 | 1.30e-04 | 1.03e-03 | 85 |
GO:000926024 | Thyroid | PTC | ribonucleotide biosynthetic process | 81/5968 | 182/18723 | 2.27e-04 | 1.65e-03 | 81 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GMPS | SNV | Missense_Mutation | | c.472G>C | p.Asp158His | p.D158H | P49915 | protein_coding | tolerated(0.05) | benign(0.151) | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
GMPS | SNV | Missense_Mutation | | c.420N>G | p.Phe140Leu | p.F140L | P49915 | protein_coding | deleterious(0) | possibly_damaging(0.784) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
GMPS | SNV | Missense_Mutation | novel | c.207N>G | p.Phe69Leu | p.F69L | P49915 | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GMPS | SNV | Missense_Mutation | | c.1783N>C | p.Ala595Pro | p.A595P | P49915 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
GMPS | SNV | Missense_Mutation | novel | c.91C>G | p.Leu31Val | p.L31V | P49915 | protein_coding | deleterious(0) | possibly_damaging(0.857) | TCGA-C5-A2LY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
GMPS | SNV | Missense_Mutation | | c.905N>T | p.Ser302Phe | p.S302F | P49915 | protein_coding | tolerated(0.06) | benign(0.127) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
GMPS | SNV | Missense_Mutation | rs879113982 | c.1913N>A | p.Arg638Gln | p.R638Q | P49915 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
GMPS | SNV | Missense_Mutation | novel | c.380N>C | p.Gly127Ala | p.G127A | P49915 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GMPS | SNV | Missense_Mutation | | c.1711N>T | p.Pro571Ser | p.P571S | P49915 | protein_coding | tolerated(0.27) | benign(0.063) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GMPS | SNV | Missense_Mutation | | c.2059N>A | p.Pro687Thr | p.P687T | P49915 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |